Alpha Teknova Inc

TKNO is in a Stage 2 corrective advance with clear higher highs and higher lows, riding above rising 9/21 EMAs and 50 DMA. Price is tightly tracking above the EMAs and holding support on shallow pullbacks, with no exhaustion evident. The medium-term bias remains bullish, and short-term timing favors immediate participation; we Buy Now on support at the EMA zone while monitoring for flattening EMA slopes and failure to reclaim June highs as potential transition risk to Stage 3.

• ↑Q1 2026 revenue rose 13% YoY to $11M; clinical solutions up 85%
• ↑2026 revenue guidance of $42–44M implies ~6% growth over 2025
• ↓Custom products (25% of sales) remain exposed to volatile biotech funding